Management of relapse and minimal residual disease after stem cell allotransplantation

Hematopoietic Stem Cell Transplantation in Clinical Practice

Volumn , Issue , 2009, Pages 409-416

  Mielke, Stephan ^a   Barrett, A John ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75049085119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-10147-2.50044-8     Document Type: Chapter

References (80)

1. Pasquini MC, Nugent ML Current use and outcome of hematopoietic stem cell transplantation: part I CIBMTR Summary Slides, 2005. CIBMTR Newsletter [serial online] 2006, 12:5-8. (accessed August 2007). http://www.cibmtr.org/ABOUT/NEWS/2006MAY.pdf.
2. Dazzi F, Fozza C Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol 2007, 20:311-327.
3. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1533.
4. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
5. Barrett AJ, Savani BN Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
6. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
7. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
8. Perez-Simon JA, Caballero D, ez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002, 16:1423-1431.
9. Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007, 13:116-123.
10. Barrett AJ, Locatelli F, Treleaven JG, et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991, 79:567-574.
11. Au WY, Kwong YL, Lie AK, et al. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 1999, 17:45-52.
12. Koc Y, Miller KB, Schenkein DP, et al. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999, 85:608-615.
13. Stein J, Zimmerman PA, Kochera M, et al. Origin of leukemic relapse after bone marrow transplantation: comparison of cytogenetic and molecular analyses. Blood 1989, 73:2033-2040.
14. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
15. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
16. Schuler F, Dolken G Detection and monitoring of minimal residual disease by quantitative real-time PCR. Clin Chim Acta 2006, 363:147-156.
17. Campana D, Coustan-Smith E Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004, 112:8-15.
18. Thiede C, Bornhauser M, Ehninger G Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol 2004, 112:16-23.
19. Muhlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromos Cancer 1998, 21:90-100.
20. Buno I, Wyatt WA, Zinsmeister AR, et al. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998, 92:2315-2321.
21. van der Velden V, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.
22. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638.
23. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
24. Mughal TI, Yong A, Szydlo RM, et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001, 115:569-574.
25. Collins RH, Rogers ZR, Bennett M, et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992, 10:391-395.
26. Nadal E, Fowler A, Kanfer E, et al. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol 2004, 32:218-223.
27. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
28. Simula MP, Marktel S, Fozza C, et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007, 21:943-948.
29. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001, 19:3675-3684.
30. Russell NH, Byrne JL, Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437-441.
31. Duus JE, Stiff PJ, Choi J, et al. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant 2005, 35:261-264.
32. Litzow MR The therapy of relapsed acute leukaemia in adults. Blood Rev 2004, 18:39-63.
33. Adachi S, Leoni LM, Carson DA, Nakahata T Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol 2004, 111:107-123.
34. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
35. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93:3678-3684.
36. Deininger M, Buchdunger E, Druker BJ The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
37. Bruno B, Patriarca F, Sorasio R, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006, 91:837-839.
38. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
39. de Raeve H, Vanderkerken K Immunomodulatory drugs as a therapy for multiple myeloma. Curr Pharm Biotechnol 2006, 7:415-421.
40. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36:1009-1015.
41. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001, 97:3589-3595.
42. Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999, 82:293-301.
43. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443.
44. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106.
45. Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1:421-432.
46. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001, 19:1485-1492.
47. Nardella FA, LeFevre JA Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Blood 2002, 99:2625-2626.
48. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994, 83:3377-3383.
49. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000, 96:2712-2716.
50. Bocchia M, Forconi F, Lauria F Emerging drugs in chronic myelogenous leukaemia. Expert Opin Emerg Drugs 2006, 11:651-664.
51. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003, 17:1707-1712.
52. Singhal S, Powles R, Treleaven J, Mehta J Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b. Bone Marrow Transplant 1997, 19:1151-1153.
53. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004, 34:721-727.
54. Mrsic M, Horowitz MM, Atkinson K, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992, 9:269-275.
55. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993, 11:304-313.
56. Blair A, Goulden NJ, Libri NA, et al. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev 2005, 19:289-300.
57. Anderlini P, Acholonu SA, Okoroji GJ, et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004, 34:511-514.
58. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103:4362-4364.
59. Falkenburg JH, Willemze R Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol 2004, 17:415-425.
60. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
61. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
62. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004, 199:885-894.
63. Barrett AJ, Rezvani K Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 2007, 148:189-198.
64. Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. ASH Annual Meeting Abstracts 2004, 104:259.
65. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
66. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1997, 74:1-6.
67. Sconocchia G, del Principe D, Barrett AJ Non-classical antileukemia activity of early recovering NK cells after induction chemotherapy and HLA-identical stem cell transplantation in myeloid leukemias. Leukemia 2006, 20:1632-1633.
68. Boyington JC, Motyka SA, Schuck P, et al. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000, 405:537-543.
69. Brooks AG, Boyington JC, Sun PD Natural killer cell recognition of HLA class I molecules. Rev Immunogenet 2000, 2:433-448.
70. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006, 107:1688-1695.
71. Passweg JR, Koehl U, Uharek L, et al. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2006, 19:811-824.
72. Koehl U, Esser R, Zimmermann S, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Paediatr 2005, 217:345-350.
73. Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004, 33:261-266.
74. Mielke S, Solomon SR, Barrett AJ Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 2005, 7:109-115.
75. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005, 106:1123-1129.
76. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of foxp3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (GvHD). Blood 2007, 110(5):1689-1697.
77. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002, 360:130-137.
78. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006, 108:1797-1808.
79. Mielke S, Nunes R, Rezvani K, et al. A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008, 111(8). in press.
80. Roy DC, Cohen S, Busque L, et al. Phase I clinical study of donor lymphocyte infusion depleted of alloreactive T cells after haplotype mismatched myeloablative stem cell transplantation to limit infections and malignant relapse without causing GVHD. ASH Annual Meeting Abstracts 2006, 108:309.